FOR RESEARCH USE ONLY
Tesamorelin

CHEMICAL PROPERTIES

CAS NUMBER218949-48-9
MOLECULAR WEIGHT5135.77 g/mol
MOLECULAR FORMULAC₂₂₁H₃₆₆N₆₄O₆₅S

PHYSICAL PROPERTIES

APPEARANCEWhite lyophilized powder in sealed borosilicate glass vial.
SEQUENCETrans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂

Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH) with a trans-3-hexenoic acid group attached to the N-terminal tyrosine. This modification significantly enhances metabolic stability compared to native GHRH, making it a well-characterized tool compound for GHRH receptor research.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-0626-TSM-013
REPORT NO.RPT-20009
HPLC PURITY98.90%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
TESTED

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation
Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007
Phase III randomised controlled trial demonstrating significant visceral fat reduction with Tesamorelin vs placebo — the pivotal trial supporting FDA approval of Egrifta.
PMID 17978289
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Ionescu M, Frohman LA. · Journal of Clinical Endocrinology & Metabolism · 2006
Human study showing sustained, pulsatile GH elevation from a long-acting GHRH analog — provides context for Tesamorelin's mechanism as an FDA-approved GHRH analog.
PMID 17018654

LAB RESULTS

LOT LMO-0626-TSM-013 · CURRENT

Certificate of Analysis

PURITY
98.90%
CAS
218949-48-9
MW
5135.77 g/mol
APPEARANCE
White lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • N-terminally modified GHRH analogue — enhanced metabolic stability vs native GHRH
  • GHRH receptor binding characterization studies
  • GH pulse amplitude and frequency research in pituitary models
  • Comparative stability studies vs Sermorelin and CJC-1295

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.

Your cart is empty

Add compounds to get started